razoxane

Razoxin

An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C801" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C801" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000039480

Razoxin

ICI 59118

ICRF 159

ICRF159

ICRF-159

21416-87-5

http://purl.bioontology.org/ontology/PDQ/CDR0000039548

C0877950

C0678114

C0034738

C5441848

2008-02-15

An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C801" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C801" NCI Thesaurus)

7651

2114

TRD

C801

CDR0000039480

129943

Drug/agent

razoxane

T109

T121